comparemela.com

Latest Breaking News On - Davida dewahl jr - Page 1 : comparemela.com

Ischemix, Inc Completes Successful Phase 1 Trial of Novel Compound to Treat Traumatic Brain Injury

CMX-2043, a novel, proprietary cytoprotective drug candidate, demonstrated excellent safety and tolerability in a Phase 1 single ascending and multiple ascending dose (SAD-MAD) clinical trial. CMX-2043 has previously demonstrated safety and efficacy in extensive preclinical pharmacology, toxicology and TBI translati.

Ischemix, Inc Completes Successful Phase 1 Trial of Novel Compound

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.